Pharmagreen Biotech Inc. Stock OTC Markets

Equities

PHBI

US00922N1046

Biotechnology & Medical Research

Delayed OTC Markets 11:11:07 2021-10-05 am EDT 5-day change 1st Jan Change
0.0289 USD -.--% Intraday chart for Pharmagreen Biotech Inc. -4.87% +172.64%
Sales 2022 - Sales 2023 0 Capitalization 401K
Net income 2022 - Net income 2023 - EV / Sales 2022 -
Net Debt 2022 331K Net Debt 2023 372K EV / Sales 2023 257,842,228 x
P/E ratio 2022
-4.61 x
P/E ratio 2023
-0.57 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 87.23%
More Fundamentals * Assessed data
Dynamic Chart
Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
Pharmagreen Biotech Inc. cancelled the transaction announced on November 2, 2022 CI
Pharmagreen Starts Sales of MaxGenomicTM Supplement on Amazon.Com and Develops Its Next Pre-Workout Formulation CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI
Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022 CI
Pharmagreen Biotech, Inc. Launches Online Sales for Its MaxGenomic(TM) Supplement Product CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Full Year Ended September 30, 2022 CI
Pharmagreen Biotech Inc. Auditor Raises 'Going Concern' Doubt CI
Pharmagreen Biotech Inc. announced that it expects to receive $0.05 million in funding from JanBella Group, LLC CI
Pharmagreen Biotech Inc. Develops a Proprietary Nutraceutical Formulation and Prepares for Product Launch CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022 CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022 CI
Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021 CI
More news
Managers TitleAgeSince
Chief Executive Officer 53 13-12-08
Director of Finance/CFO 77 15-07-21
Chief Tech/Sci/R&D Officer - 22-09-21
Members of the board TitleAgeSince
Chief Executive Officer 53 13-12-08
Director of Finance/CFO 77 15-07-21
More insiders
Pharmagreen Biotech, Inc. is a Canada-based company. The Company is engaged in developing its line of nutraceutical products, which is a blend of therapeutic plants and mushrooms. Utilizing the Company's expertise in plant genetics, its transgenic program uses the technology available to research and create nutraceuticals, and daily supplements with the potential to improve lives and address a wide variety of ailing conditions. Its nutraceutical product, MaxGenomic Supplement, comes in a bottle with 60 enteric capsules. The MaxGenomic Supplement is a proprietary blend that consists of nine medicinal mushrooms and six medical plants to help support the human mind and body. Its other nutraceutical products are in various development stages. Its subsidiaries include WFS Pharmagreen Inc, and 1155097 BC Ltd.
More about the company